---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-036445"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:36:06.868544+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Niagen subsidiary ChromaDex signs exclusive NRCL supply deal with W.R. Grace through 2029

## Summary
- Exclusive supply of Nicotinamide-beta-Riboside Chloride (NRCL); Grace cannot sell to third parties.
- Initial term through April 30, 2029, with automatic 12-month renewals unless 90-day non-renewal notice.
- ChromaDex must purchase minimum annual quantities and provide rolling 24-month forecasts with first 12 months binding.
- Parties will negotiate a royalty-bearing license to Grace's NRCL manufacturing patents upon termination under specified conditions.
- 2025 product price set at $[***]/kg; each party may propose up to 5% price adjustment twice per year.

## SEC filing metadata
- accession: 0001628280-25-036445
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000162828025036445/0001628280-25-036445-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000162828025036445/cdxc-20250725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-036445
- JSON: https://secwatch.observer/filing/0001628280-25-036445.json
- Plain text: https://secwatch.observer/filing/0001628280-25-036445.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.